altern
splice
enabl
singl
premesseng
rna
transcript
yield
multipl
protein
isoform
make
major
contributor
divers
proteom
process
essenti
normal
develop
aberr
altern
splice
caus
multitud
human
diseas
method
manipul
altern
splice
would
thu
therapeut
valu
chemic
modifi
ed
antisens
oligonucleotid
alter
altern
splice
direct
splice
site
select
develop
achiev
end
spliceswitch
oligonucleotid
sso
appli
correct
aberr
splice
induc
express
therapeut
splice
variant
induc
express
novel
therapeut
splice
variant
number
diseaserelev
gene
recent
vivo
effi
caci
sso
report
use
anim
diseas
model
well
result
fi
rst
clinic
trial
ltern
splice
essenti
biolog
process
import
implic
human
diseas
earli
work
laboratori
demonstr
antisens
oligonucleotid
could
use
correct
aberrantli
splice
human
premesseng
rna
premrna
cellfre
extract
cultur
erythroid
cell
patient
dominski
kole
sierakowska
et
al
kole
lacerra
et
al
sinc
other
employ
spliceswitch
oligonucleotid
sso
numer
applic
target
mani
diseaserelev
gene
kole
et
al
recent
sever
group
report
advanc
use
sso
anim
model
human
diseas
importantli
clinic
trial
use
sso
treat
duchenn
muscular
dystrophi
gener
posit
result
patient
review
cover
recent
develop
applic
sso
therapeut
relev
target
emphasi
diseas
model
tabl
altern
splice
biolog
process
regul
gene
express
higher
eukaryot
gener
multipl
protein
isoform
divers
function
singl
premrna
transcript
matlin
et
al
therefor
contribut
signifi
cantli
divers
proteom
inde
human
gene
predict
undergo
altern
splice
mironov
et
al
johnson
et
al
importantli
human
genet
diseas
aris
mutat
affect
splice
emphas
need
drug
manipul
splice
faustino
cooper
pagani
baral
pagenstech
et
al
premrna
splice
mediat
spliceosom
dynam
complex
protein
rna
assembl
de
novo
everi
splice
event
sequenc
specifi
citi
simultan
plastic
altern
splice
achiev
tissu
depend
variabl
spliceosom
composit
pollard
et
al
pollard
et
al
loos
conserv
essenti
sequenc
element
premrna
element
includ
splice
site
branch
point
polypyrimidin
tract
auxiliari
exon
intron
sequenc
element
known
splice
enhanc
ese
ise
respect
silenc
esss
isss
respect
splice
thought
control
competit
among
splice
site
splice
element
splice
factor
spliceosom
base
splice
site
usag
singl
premrna
transcript
altern
splice
produc
multipl
matur
mrna
splice
variant
translat
variabl
protein
isoform
accomplish
variou
mean
includ
exon
exclus
intron
retent
exon
shuffl
ing
altern
splice
site
altern
promot
altern
polyadenyl
site
fig
matlin
et
al
altern
splice
also
downregul
gene
express
local
system
dystrophin
induct
mdx
mice
mann
et
al
lu
et
al
lu
et
al
clinic
trial
dmd
patient
intramuscular
inject
van
deutekom
et
al
pmo
function
level
dystrophin
induct
bodywid
skelet
muscl
mdx
mice
system
deliveri
pmo
alter
et
al
doseescal
clinic
trial
dmd
patient
singl
intramuscular
inject
imperi
colleg
london
uk
progress
ppmo
effect
dystrophin
restor
bodywid
muscl
includ
cardiac
muscl
mdx
mice
jearawiriyapaisarn
et
al
ppmo
restor
hba
product
erythroid
cell
peripher
blood
thalassem
patient
free
uptak
pmo
suwanmane
et
al
suwanmane
et
al
spinal
muscular
atrophi
introduct
prematur
stop
codon
lead
nonsensemedi
decay
transcript
lewi
et
al
dynam
natur
gene
tissu
depend
variabl
splice
machineri
interact
premrna
suggest
rich
potenti
target
drug
interfer
redirect
altern
splice
pathway
therapeut
purpos
spliceswitch
oligonucleotid
direct
premrna
splice
bind
sequenc
element
block
access
transcript
spliceosom
splice
factor
appli
restor
correct
splice
aberrantli
splice
transcript
produc
novel
splice
variant
normal
express
manipul
altern
splice
one
splice
variant
anoth
fig
latter
mechan
sso
therefor
downregul
deleteri
transcript
simultan
upregul
express
prefer
transcript
notabl
activ
enhanc
increas
target
gene
express
enabl
increas
product
prefer
splice
variant
mercatant
et
al
contrast
tradit
antisens
approach
smallinterf
rna
exhibit
decreas
potenc
increas
target
gene
express
direct
splice
sso
requir
target
premrna
duplex
compound
degrad
rnase
h
requir
distinguish
sso
mechan
tradit
antisens
rnai
degrad
mrna
downregul
gene
express
desir
achiev
primarili
alter
oligonucleotid
sugarphosph
backbon
exampl
includ
phosphorodiamid
morpholino
pmo
peptid
nucleic
acid
pna
lock
nucleic
acid
lna
moe
ribos
modifi
cation
fig
kurreck
addit
rnase
h
resist
sso
modifi
cation
impart
increas
target
affi
niti
uniqu
exploit
function
distribut
profi
le
vivo
sazani
et
al
exampl
lna
sso
demonstr
potent
persist
activ
confi
ned
almost
exclus
liver
small
intestin
colon
robert
et
al
pmo
sso
exhibit
peptidedepend
function
biodistribut
larg
number
tissu
jearawiriyapaisarn
et
al
spliceswitch
oligonucleotid
may
also
incorpor
phosphorothio
ps
linkag
confer
rnase
h
resist
contribut
increas
serum
stabil
bioavail
sso
direct
altern
splice
therapeut
approach
also
provid
mean
assay
improv
cell
cultur
vivo
activ
sso
particularli
use
report
system
either
luciferas
enhanc
green
fl
uoresc
protein
egfp
code
sequenc
interrupt
aberrantli
splice
human
intron
develop
laboratori
kang
et
al
sazani
et
al
sazani
et
al
function
luciferas
egfp
protein
express
sso
success
enter
cell
access
nuclear
premrna
bind
sequenc
element
intron
prompt
correct
splice
exclus
intron
mrna
transcript
transgen
mous
provid
function
positivereadout
platform
assess
sso
effi
caci
vivo
sazani
et
al
robert
et
al
report
system
also
use
evalu
variou
enhanc
sso
deliveri
includ
cellpenetr
peptid
jearawiriyapaisarn
et
al
group
employ
luciferasebas
cell
system
evalu
receptor
ligand
alam
et
al
nanoparticl
carrier
liu
franzen
sso
uptak
resina
et
al
resina
et
al
wu
et
al
lebleu
et
al
duchenn
muscular
dystrophi
dmd
fatal
genet
diseas
character
sever
progress
muscl
wast
caus
delet
mutat
dmd
gene
caus
prematur
termin
translat
result
lack
dystrophin
protein
delet
maintain
read
frame
dmd
gene
produc
intern
delet
partial
function
dystrophin
caus
milder
becker
muscular
dystrophi
bmd
monaco
et
al
report
rare
natur
occur
dystrophinposit
revert
fi
ber
found
muscl
section
mdx
mous
mous
model
dmd
hoffman
et
al
dmd
patient
nicholson
et
al
dystrophin
revert
fi
ber
intern
delet
dystrophin
gener
remov
mutat
exon
restor
translat
read
frame
dmd
transcript
altern
splice
pathway
dystrophin
premrna
klein
et
al
lu
et
al
goal
dmd
research
mimic
natur
phenomenon
convert
dmd
phenotyp
bmd
phenotyp
remov
one
exon
creat
shorten
infram
dystrophin
transcript
gener
partial
function
dystrophin
approach
valid
use
sso
block
premrna
splice
element
therebi
exclud
mutationcontain
exon
restor
read
frame
dmd
transcript
cellfre
extract
takeshima
et
al
human
lymphoblastoid
cell
pramono
et
al
primari
mdx
myoblast
cultur
dunckley
et
al
wilton
et
al
use
sso
mediat
exon
skip
dmd
recent
progress
cell
cultur
anim
model
clinic
trial
sso
chemistri
fi
rst
use
dmd
studi
dmd
treatment
laboratori
recent
demonstr
fi
rst
time
system
treatment
mdx
mice
ppmob
carri
rxrrbr
xb
peptid
induc
cardiac
muscl
high
level
exon
mrna
produc
normal
dystrophin
protein
treatment
result
reduc
infl
ammatori
cell
infi
ltration
heart
jearawiriyapaisarn
et
al
exon
mrna
restor
product
dystrophin
protein
remain
detect
least
month
treatment
especi
diaphragm
quadricep
exon
skip
maintain
suggest
ppmob
pmo
stabl
muscl
tissu
halflif
dystrophin
mrna
hour
tennyson
et
al
sustain
dystrophin
express
heart
also
bodywid
muscl
fig
led
decreas
serum
ck
near
wildtyp
level
confi
rming
rescu
dystrophin
protein
function
sustain
dystrophin
express
induc
ppmob
sso
would
desir
clinic
applic
due
potenti
infrequ
readministr
therefor
spliceswitch
ppmob
hold
great
potenti
treatment
dmd
preclin
studi
extend
test
sequenc
specifi
citi
dose
regimen
sso
transgen
hdmd
mice
carri
fulllength
human
dmd
gene
hoen
et
al
intramuscular
inject
sso
exclud
target
human
exon
without
affect
endogen
mous
dystrophin
transcript
suggest
high
sequenc
specifi
citi
obtain
bremmerbout
et
al
preclin
result
describ
led
three
clinic
trial
oligonucleotideinduc
exonskip
dmd
patient
first
ps
oligodeoxynucleotid
evalu
dmd
boy
carri
outoffram
dmd
transcript
caus
delet
exon
takeshima
et
al
compound
target
splice
enhanc
sequenc
exon
report
exclud
exon
gener
shorten
infram
transcript
low
level
transcript
lack
exon
posit
dystrophin
muscl
fi
ber
identifi
ed
muscl
biopsi
week
four
weekli
iv
infus
mgkg
observ
surpris
sinc
oligodeoxynucleotid
induc
rnase
h
mediat
rna
degrad
capabl
splice
modul
perhap
one
reason
treatment
improv
muscl
function
robust
welldesign
clinic
trial
sso
target
intern
sequenc
exon
induc
exon
skip
van
deutekom
et
al
studi
demonstr
singl
local
im
inject
mg
specifi
calli
exclud
exon
four
patient
dmd
restor
translat
read
frame
led
product
truncat
dystrophin
normal
level
total
protein
lysat
extract
muscl
biopsi
taken
week
inject
function
improv
inject
muscl
observ
final
doseescal
clinic
trial
pmo
sso
design
skip
exon
underway
studi
intend
establish
efficaci
safeti
singl
im
inject
nine
boy
dmd
system
administr
also
develop
preclin
studi
futur
phase
ii
iii
clinic
trial
http
clinicaltrialsgov
skip
exon
could
rescu
dmd
patient
suffer
exon
phosphorothio
test
primari
myoblast
deriv
dmd
patient
carri
differ
delet
nonsens
mutat
van
deutekom
et
al
aartsmaru
et
al
mdx
mice
carri
nonsens
mutat
exon
dmd
gene
dystrophin
express
restor
intramuscular
im
inject
sso
target
splice
site
intron
complex
liposom
mann
et
al
nonion
block
copolym
lu
et
al
latter
case
sso
treatment
led
function
improv
treat
muscl
sinc
bodywid
muscl
affect
dmd
import
induc
dystrophin
express
muscl
skelet
smooth
cardiac
muscl
intraven
iv
inject
complex
induc
dystrophin
express
bodywid
skelet
muscl
cardiac
muscl
mdx
mice
detect
toxic
lu
et
al
addit
pmo
also
employ
mdx
mice
pmo
anneal
neg
charg
dna
sens
strand
leash
complex
liposom
effect
induc
exon
skip
mdx
mice
local
gebski
et
al
fletcher
et
al
system
inject
fletcher
et
al
step
forward
achiev
mdx
mice
iv
inject
mg
uncomplex
pmo
sso
weekli
interv
led
function
improv
tibiali
anterior
muscl
three
inject
alter
et
al
seven
weekli
inject
level
dystrophin
express
gastrocnemiu
quadricep
treat
mdx
mice
reach
normal
level
level
serum
creatinin
kinas
ck
dramat
reduc
suggest
integr
muscl
sarcolemma
improv
ssoinduc
dystrophin
product
administr
uncomplex
pmo
simpl
would
ideal
clinic
applic
potenti
pmo
dystrophin
induct
also
shown
canin
xlink
muscular
dystrophi
cxmd
clinic
sever
canin
model
dmd
system
infus
pmo
cocktail
induc
skip
exon
restor
dystrophin
express
skelet
muscl
amelior
exercis
abil
cxmd
canin
yokota
et
al
chemistri
lna
ethylen
bridg
nucleic
acid
ena
pna
test
cell
cultur
vivo
seem
particularli
use
treatment
dmd
aartsmaru
et
al
surono
et
al
yin
et
al
major
advanc
oligomerinduc
exon
skip
dmd
applic
cellpenetratingpeptideconjug
pmo
ppmo
compound
shown
enhanc
effi
caci
exon
remov
mdx
mice
compar
unconjug
pmo
ppmo
carri
rxr
xb
peptid
r
arginin
x
acid
b
induc
normal
level
dystrophin
express
diaphragm
low
level
colon
gut
skelet
muscl
mdx
mice
treat
neonat
four
weekli
intraperiton
ip
inject
mgkg
signifi
cantli
lower
dose
use
unconjug
pmo
moulton
et
al
howev
none
studi
anim
model
show
restor
dystrophin
express
cardiac
muscl
intracardiac
inject
pmo
mdx
mice
induc
low
level
dystrophin
express
vitiello
et
al
cardiomyopathi
one
major
caus
death
dmd
patient
induct
dystrophin
express
cardiac
muscl
critic
intron
three
intron
mutat
c
g
c
g
creat
aberr
splice
site
activ
common
cryptic
splice
site
posit
intron
use
aberr
splice
site
gener
mrna
transcript
includ
intron
sequenc
encod
stop
codon
result
translat
truncat
nonfunct
protein
mutat
extens
studi
target
sso
cellfre
extract
model
cell
line
stabli
express
mutant
sierakowska
et
al
schmajuk
et
al
erythroid
progenitor
cell
isol
peripher
blood
patient
carri
mutat
singl
treatment
pmo
target
aberr
splice
site
syring
load
result
correct
premrna
splice
product
hba
lacerra
et
al
moreov
pmo
freeli
taken
erythroid
progenitor
cell
isol
bone
marrow
mice
carri
human
mutat
lewi
et
al
peripher
blood
patient
carri
mutat
lead
effect
splice
correct
suwanmane
et
al
signifi
cant
hba
upregul
achiev
treat
human
thalassem
erythroid
precursor
target
cell
thalassemia
treatment
free
uptak
pmo
also
shown
effect
splice
correct
hba
restor
progenitor
cell
isol
patient
carri
hbe
mutat
activ
cryptic
splice
site
exon
suwanmane
et
al
result
suggest
pmo
would
applic
vivo
mous
model
delet
fig
recent
report
invers
exon
madden
et
al
affect
estim
dmd
patient
limit
exon
skip
strategi
dmd
skip
one
exon
could
restor
translat
read
frame
particular
delet
optim
sso
differ
delet
person
molecular
medicin
may
necessari
hoffman
howev
current
regulatori
hurdl
requir
individu
drug
make
approach
prohibit
expens
commerci
develop
overcom
limit
multipleexon
skip
increas
number
delet
case
might
benefi
strategi
explor
aartsmaru
et
al
predict
multipleexon
skip
exon
could
appli
dmd
patient
beroud
et
al
still
unansw
question
regard
sso
bioavail
therapeut
index
longterm
effect
address
ongo
preclin
clinic
studi
result
like
among
therapeut
applic
sso
exon
skip
dmd
fi
rst
use
clinic
genet
blood
disord
character
defi
cienci
chain
lead
reduct
absenc
adult
hemoglobin
hba
gene
mutat
alter
premrna
splice
found
intron
sso
impair
splice
site
recognit
forc
splice
machineri
recoupl
splice
site
intron
lead
increas
inclus
exon
cell
cultur
lim
hertel
target
exon
sso
either
link
serineargininerich
splice
factor
includ
tail
serv
splice
factorbind
site
call
exon
specifi
csplice
enhanc
small
chimer
effector
essenc
target
oligonucleotid
enhanc
splice
toe
skordi
et
al
respect
also
shown
promot
exon
inclus
synthet
essenc
molecul
contain
pna
sso
target
exon
coupl
arginineserin
rs
repeat
signifi
cantli
induc
exon
inclus
cell
freesplic
system
although
pna
sso
lack
rs
repeat
activ
effi
caci
much
lower
essenc
molecul
toe
design
two
compon
fi
rst
complementari
exon
second
noncomplementari
sequenc
design
mimic
ese
recruit
transsplic
factor
bifunct
sso
increas
exon
inclus
vitro
sma
patient
fi
broblast
led
partial
restor
gem
number
indic
smn
protein
increas
suggest
sso
bound
exon
transcript
interfer
translat
spinal
muscular
atrophi
sma
character
progress
degener
motor
neuron
lead
gener
muscl
weak
spinal
muscular
atrophi
caus
homozyg
mutat
delet
surviv
motor
neuron
gene
encod
ubiquit
express
smn
protein
necessari
assembl
snrnp
involv
splice
essenti
process
cell
surviv
wan
et
al
human
second
smn
gene
copi
differ
ctot
transit
posit
exon
propos
transit
disrupt
ese
sequenc
creat
ess
sequenc
kashima
manley
strengthen
inhibitori
rna
stem
loop
end
exon
singh
et
al
lead
exon
exclus
transcript
yield
unstabl
truncat
smn
protein
modifi
gene
sma
patient
number
copi
invers
correl
sever
sma
mailman
et
al
therefor
strategi
includ
exon
upregul
express
fulllength
fulli
function
smn
protein
intact
copi
present
sma
patient
offer
therapeut
approach
sma
inde
mask
splice
site
intron
use
ssoinduc
mous
serum
potent
mice
treat
etanercept
evid
etanercept
subject
vivo
degrad
reduc
activ
continu
induc
addit
protein
replenish
degrad
inactiv
protein
circul
importantli
ssoinduc
toxic
report
sso
induc
express
endogen
protein
likelihood
immun
toxic
low
abil
sso
produc
therapeut
splice
variant
extend
time
period
low
likelihood
immun
toxic
distinct
advantag
biolog
drug
etanercept
mous
model
infl
ammatori
liver
diseas
inject
ip
day
mgkgday
protect
liver
insult
prevent
liver
damag
observ
antiinfl
ammatori
effect
like
enhanc
abil
simultan
downregul
induc
liver
importantli
etanercept
administ
dose
compar
amount
induc
elicit
protect
dose
regimen
also
delay
cours
diseas
mous
model
collageninduc
rheumatoid
arthriti
result
notabl
given
rheumatoid
arthriti
patient
respond
current
avail
drug
treatment
pincu
et
al
olsen
stein
adapt
protein
mediat
proinfl
ammatori
cytokin
signal
toll
receptor
upon
receptor
activ
interact
receptor
intracellular
domain
recruit
lead
phosphoryl
subsequ
activ
transcript
factor
natur
occur
splice
variant
result
exon
exclus
retain
receptorbind
function
defect
abil
recruit
induc
activ
result
function
dominantneg
regul
toll
receptor
signal
janssen
et
al
vicker
et
al
screen
moep
sso
target
splice
site
exon
select
isi
sso
switch
splice
mous
human
cell
isi
induc
redirect
mrna
splice
liver
adipos
tissu
intestin
mice
ip
inject
three
time
per
week
week
mgkg
sso
although
protein
detect
regimen
abrog
proinfl
ammatori
signal
liver
vicker
et
al
dystrophia
myotonica
type
common
muscular
dystrophi
among
adult
caus
amplifi
ed
ctg
repeat
untransl
region
dystrophia
myotonia
protein
kinas
dmpk
gene
brook
et
al
dmpk
transcript
contain
amplifi
ed
cug
repeat
cug
amp
caus
abnorm
regul
altern
splice
select
affect
specifi
c
group
gene
includ
chlorid
channel
mankodi
et
al
interestingli
misregul
splice
caus
inclus
exon
found
necessari
develop
myotonia
two
mous
subsequ
studi
exon
satur
overlap
moe
sso
hua
et
al
cell
cultur
experi
reveal
effect
sso
promot
exon
inclus
increas
fulllength
smn
protein
sma
patient
fi
broblast
target
two
put
esss
close
splice
site
respect
result
impli
block
ess
suffi
cient
induc
exon
inclus
essenc
toe
modifi
cation
although
likley
help
essenti
sso
target
put
iss
intron
identifi
ed
also
prompt
increas
exon
inclus
context
minigen
miyajima
et
al
iss
call
subsequ
identifi
ed
immedi
downstream
splice
site
intron
singh
et
al
extens
sso
screen
sequenc
downstream
splice
site
intron
identifi
ed
iss
hua
et
al
recent
moep
sso
target
administ
human
transgen
mice
biweekli
iv
inject
mgkg
signifi
cant
exon
inclus
observ
liver
kidney
spinal
cord
treat
mice
hua
et
al
order
achiev
therapeut
effect
strategi
sma
sso
would
need
cross
bloodbrain
barrier
deliv
directli
central
nervou
system
cn
remain
major
obstacl
gene
therapi
cn
target
cytokin
tumor
necrosi
play
import
role
infl
ammatori
diseas
rheumatoid
arthriti
hepat
signal
mediat
two
membranebound
receptor
trimer
upon
ligand
bind
lead
downstream
activ
transcript
factor
nuclear
factor
nf
approv
macromolecular
biolog
drug
etanercept
dimer
receptor
fc
fusion
protein
infl
iximab
adalimumab
monoclon
antibodi
bind
circul
block
infl
ammatori
effect
research
laboratori
hypothes
exclus
transmembran
domainencod
exon
would
creat
novel
solubl
protein
capabl
antagon
signal
fig
screen
sso
consist
altern
lnadna
nucleotid
ps
linkag
mous
cell
identifi
ed
effi
cientli
block
splice
site
exon
premrna
induc
exon
skip
sequencespecifi
c
dosedepend
manner
exon
skip
result
express
solubl
protein
detect
cultur
medium
exhibit
antitnf
activ
graziewicz
et
al
lock
nucleic
acid
sso
except
potent
liver
highli
express
robert
et
al
led
approach
util
liver
protein
factori
produc
solubl
releas
circul
antagon
expect
induc
sequencespecifi
c
dosedepend
persist
splice
switch
mous
liver
daili
ip
injecton
protein
detect
serum
anim
pgml
exhibit
potent
antitnf
activ
detect
circul
day
last
inject
interestingli
manner
therebi
downregul
fulllength
produc
novel
splice
variant
lack
transmembran
domain
human
breast
cancer
cell
highli
express
splice
switch
potent
inhibit
cell
growth
induc
apoptosi
effect
less
pronounc
cell
express
lower
despit
fact
splice
switch
still
observ
confi
rming
growth
inhibit
consist
previous
report
correl
sso
potenc
increas
target
gene
express
mercatant
et
al
also
indic
tumor
highli
express
would
sensit
sso
treatment
surround
healthi
tissu
protein
encod
ssoinduc
mrna
could
detect
demonstr
protein
potent
downregul
protein
express
inhibit
activ
dosedepend
manner
ad
exogen
cell
wan
et
al
ataxiatelangiectasia
autosom
recess
disord
character
neurodegener
immun
defect
predisposit
malign
ataxiatelangiectasia
caus
mutat
mutat
atm
gene
half
disrupt
splice
teraoka
et
al
recent
pmo
sso
use
block
activ
cryptic
splice
site
cell
line
repres
three
type
splice
defect
exon
cryptic
splice
site
tat
c
cell
exon
cryptic
splice
site
cell
pseudoexon
inclus
cell
du
et
al
case
dosedepend
sequencespecifi
c
splice
correct
achiev
lead
upregul
function
atm
protein
fi
nding
especi
promis
light
evid
small
amount
function
protein
wildtyp
level
necessari
signifi
cantli
amelior
diseas
phenotyp
gilad
et
al
apolipoprotein
b
apob
primari
apolipoprotein
lowdens
lipoprotein
ldl
lowdens
lipoprotein
vldl
intermediatedens
lipoprotein
idl
lipoprotein
lp
chylomicron
lipoprotein
particl
apolipoprotein
b
express
two
protein
isoform
result
inclus
exon
apob
premrna
necessari
synthesi
ldl
lp
particl
liver
contribut
atherogenesi
thu
target
downregul
strategi
lower
ldl
cholesterol
level
treatment
prevent
cardiovascular
diseas
soutschek
et
al
zimmermann
et
al
ctermin
truncat
protein
result
tissuespecifi
c
rna
edit
exon
introduc
prematur
stop
codon
express
intestin
necessari
chylomicron
assembl
intestin
fat
transport
order
downregul
without
affect
express
khoo
et
al
design
sso
aim
skip
exon
creat
novel
splice
variant
could
mimic
function
model
hsa
lr
mice
wheeler
et
al
inclus
exon
caus
introduct
prematur
stop
codon
translat
nonfunct
truncat
protein
wheeler
et
al
screen
pmo
sso
target
splice
site
exon
restor
normal
splice
sso
simultan
inject
tibiali
anterior
muscl
hsa
lr
mice
accompani
voltag
puls
electropor
muscl
fi
ber
improv
uptak
singl
inject
sso
induc
sequencespecifi
c
exon
skip
persist
least
week
spliceswitch
oligonucleotideinduc
splice
switch
increas
level
wildtyp
protein
rescu
channel
function
revers
myotonia
skelet
muscl
similar
result
observ
mice
wheeler
et
al
ssobas
strategi
noteworthi
affect
propos
underli
mechan
diseas
wherea
current
avail
drug
provid
partial
relief
symptom
trip
et
al
menk
diseas
xlink
recess
disord
caus
gener
copper
defi
cienci
character
growth
retard
neurodegener
lead
death
earli
infanc
menk
et
al
caus
lossoffunct
mutat
gene
encod
ptype
atpas
necessari
copper
absorpt
homeostasi
lutsenko
et
al
splice
defect
zebrafi
sh
ortholog
produc
calam
zebrafi
sh
model
menk
phenotyp
mendelsohn
et
al
defect
calam
caus
creation
aberr
splice
site
exon
screen
pmo
sso
target
aberr
splice
site
madsen
et
al
identifi
ed
two
sso
restor
normal
splice
wildtyp
protein
product
calam
embryo
madsen
et
al
importantli
singl
inject
pmo
sso
achiev
full
rescu
mutant
phenotyp
persist
least
day
fertil
untreat
calam
embryo
dead
dysmorph
madsen
et
al
belong
epiderm
growth
factor
receptor
egfr
famili
receptor
tyrosin
kinas
amplifi
ed
overexpress
mani
human
cancer
includ
breast
cancer
increas
express
associ
increas
tumor
aggress
decreas
surviv
although
known
ligand
form
constitut
activ
homodim
cell
signal
mitogenactiv
protein
kinas
phosphatidylinositol
pathway
addit
ligandinduc
activ
egfr
famili
member
preferenti
recruit
form
activ
heterodim
herstatin
natur
occur
splice
variant
produc
intron
inclus
function
neg
regul
signal
doherti
et
al
develop
herstatinlik
antagonist
laboratori
screen
seri
moep
sso
design
modul
splice
premrna
induc
exon
skip
sequencespecifi
c
dosedepend
jearawiriyapaisarn
et
al
human
diseasecaus
mutat
affect
splice
sso
approach
emerg
promis
altern
gene
therapi
interestingli
sso
target
either
splice
site
exon
branch
point
intron
ineffect
induc
exon
skip
howev
sso
target
two
sequenc
simultan
achiev
exon
skip
dosedepend
sequencespecifi
c
manner
sso
target
put
exon
splice
enhanc
motif
within
exon
albeit
lesser
degre
khoo
et
al
author
show
ssoinduc
skip
exon
result
translat
isoform
protein
secret
cell
cultur
khoo
et
al
propion
methylmalon
acidemia
two
frequent
organ
acidemia
character
lack
propionyl
coenzym
carboxylas
pcc
methylmalonylcoa
mutas
mcm
respect
enzym
involv
catabol
amino
acid
oddchain
fatti
acid
cholesterol
subunit
pcca
subunit
pccb
gene
encod
two
subunit
pcc
enzym
mut
gene
encod
mcm
enzym
g
mutat
pcca
intron
creat
novel
ese
sequenc
favor
cryptic
splice
site
pseudoexon
g
mutat
pccb
intron
c
mutat
mut
intron
increas
cryptic
splice
site
score
pseudoexon
three
mutat
intron
promot
inclus
pseudoexon
mrna
result
frameshift
mutat
gener
transcript
contain
prematur
termin
codon
lead
product
truncat
nonfunct
protein
block
either
cryptic
splice
site
pmo
complex
peptid
carrier
endoport
gene
tool
restor
almost
correct
splice
fi
broblast
patient
carri
mutat
pcca
pccb
mut
ugart
et
al
correctli
splice
mut
mrna
persist
day
treatment
confi
rming
pmo
stabl
cell
enzymat
activ
pcc
mcm
fulli
recov
treatment
result
notabl
given
normal
enzymat
activ
necessari
therapeut
effect
sinc
sever
oligonucleotid
modifi
cation
effi
cientli
deliv
liver
target
tissu
diseas
multipl
potenti
avenu
therapeut
applic
vivo
number
clinic
relev
target
sso
expand
sinc
technolog
pioneer
laboratori
dominski
kole
among
target
dmd
current
test
clinic
trial
promis
recent
result
dmd
patient
work
van
deutekom
et
al
suggest
sso
constitut
realist
approach
therapeut
applic
advantag
approach
sso
target
premrna
transcrib
nativ
gene
normal
regulatori
environ
therebi
avoid
problem
inappropri
transgen
express
convent
gene
therapi
deliveri
remain
major
obstacl
cellpenetr
peptid
shown
signifi
cantli
enhanc
sso
deliveri
without
toxic
